Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tc 99m sestamibi Clear all
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 30, 2026, 11:03 AM EDT
Completed No phase listed Observational

Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease

NCT01545622
View directory record Official record
Conditions
Parathyroid Disease
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

NCT00162331
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Not applicable Interventional

New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer

NCT00566085
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Sep 30, 2026, 11:03 AM EDT
Not yet recruiting Phase 2 Interventional

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

NCT01899833
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
99mTc-Sestamibi
Diagnostic Test
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

NCT01347710
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
73
States / cities
Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 30, 2026, 11:03 AM EDT
Recruiting Phase 2Phase 3 Interventional

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

NCT05891769
View directory record Official record
Conditions
Parathyroid Adenoma
Interventions
18Fluorocholine
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

NCT02160925
View directory record Official record
Conditions
Clinical T1 Renal Mass
Interventions
Preoperative 99mTc-Sestamibi SPECT/CT
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 30, 2026, 11:03 AM EDT
Active, not recruiting No phase listed Observational

SPECT/CT for the Characterization of Renal Masses

NCT03996850
View directory record Official record
Conditions
Kidney Neoplasm, Renal Mass
Interventions
Computed Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sestamibi
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

NCT01334918
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast, Single Photon Emission Computed Tomography, Multidetector Computed Tomography
Drug · Radiation · Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Roseville, California • Torrance, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT01925170
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
1,638 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Molecular Breast Imaging in Patients With a History of Bloody Nipple Discharge

NCT00566280
View directory record Official record
Conditions
Breast Cancer, Bloody Nipple Discharge
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 75 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Sep 30, 2026, 11:03 AM EDT
Recruiting Not applicable Interventional

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

NCT05042687
View directory record Official record
Conditions
Breast Cancer
Interventions
Tc99m sestamibi
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT00620373
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
969 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Sep 30, 2026, 11:03 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00560495
View directory record Official record
Conditions
Lung Cancer
Interventions
ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis, Tc 99m sestamibi, radiation therapy
Drug · Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 30, 2026, 11:03 AM EDT
Recruiting No phase listed Observational

Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

NCT05728957
View directory record Official record
Conditions
Kidney Tumor, Renal Benign Neoplasm, Renal Malignant Tumor
Interventions
Not listed
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 30, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography

NCT01434641
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
low-dose stress MPI SPECT
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Sep 30, 2026, 11:03 AM EDT
Active, not recruiting Not applicable Interventional

Tc99m Sestamibi Molecular Breast Imaging

NCT02324387
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging (MBI), Tc99m sestamibi
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 30, 2026, 11:03 AM EDT